Form 4: Clene Inc. Director Arjun Desai Receives Stock Options

Director Arjun Desai was granted 3,658 stock options in Clene Inc. as part of the company's 2020 Stock Plan.

Summary

• Director Arjun Desai received two grants of stock options on May 21, 2026.
• The total grant consists of 3,658 options for common stock.
• The exercise price for all granted options is $6.81 per share.
• 1,500 options vest in 12 equal monthly installments starting June 21, 2026.
• 2,158 options vested immediately upon the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Director compensation aligns with shareholder interests through equity-based incentives.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Future share price performance is required for the options to have intrinsic value above the $6.81 strike price.

Future Outlook

The options vest over a period ending in 2027, with an expiration date of May 20, 2036, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure alignment between board members and long-term company performance in the biotechnology sector.

Comparison to Industry Standards

• The use of the 2020 Stock Plan for director compensation is consistent with standard practices for small-cap biotechnology firms.
• Immediate vesting of a portion of the grant is a common mechanism for director compensation in lieu of cash retainers.

Stakeholder Impact

• Shareholders may experience minor dilution upon the exercise of these options.

Next Steps

• Monthly vesting of 1,500 options beginning June 21, 2026.

Key Dates

Keywords

Clene Inc, CLNN, Form 4, Insider Trading, Stock Options, Director Compensation